Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07360587

Thyroid Artery Embolization for the Treatment of Compressive Goiters.

Very few studies have investigated TAE as a treatment for goiter with compressive symptoms. What is the efficacy and safety of TAE for the treatment of compressive goiters in a population ineligible for or refusing standard therapy? This is a prospective interventional cohort study that will allow us to standardize imaging by improving quality data collection and fellow-up to assess the efficacy of TAE for compressive symptoms of nodular goiters. Not only to corroborate current emerging results but clearly define the expected results for this technique.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Thyroid Nodules Endocrine Gland Neoplasms Endocrine System Diseases Goiter Head and Neck Neoplasms Neoplasms Neoplasms by Site Thyroid Diseases Thyroid Neoplasms Thyroid Nodule

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study is a prospective interventional cohort study.

The prospective cohort setting allows us to evaluate the direct effect of TAE on a series of patients on a longer period and to strengthen the retrospective data previously documented in other studies.

Included patients will have compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter.

They have to be Ineligible for surgery/ablative treatments or preference for TAE over other treatments.

There is no comparative group in our study as it aims to prove that TAE is effective and safe in a "nonsurgical" population, a population in which other alternatives lack or are refused by the patient.

Our sampling method will be a non-probabilistic convenience sampling. Patients will be recruited in an outpatient setting by the patient's treating endocrinologist or otolaryngologist.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with compressive symptoms or significant tracheal or oesophageal compression at risk of causing symptoms attributed to a goiter AND
  • Ineligible for surgery/ablative treatments or preference for TAE over other treatments AND
  • TiRADS category 1, 2, 3 or 4 AND
  • Bethesda categories I or III on 2 different biopsies OR Bethesda II on one biopsy AND
  • Patient at least 18 years old.

Exclusion criteria

  • Comorbidities precluding endovascular procedure OR
  • TiRADS category 5 OR
  • Bethesda categories IV, V, VI on biopsy OR
  • Refusal of the patient to participate OR
  • Uncontrolled severe hyperthyroidism OR
  • Minor patient.

Treatment and study plan

Thyroid artery embolization

Procedure

Interruption of blood flow that supplies thyroid nodule using embolization technique.

Primary outcomes

  1. Change in Thyroid nodule volume

    Time frame: Follow-ups at 1 week, and 3 months, 6 months and 12 months post-op.

    TAE effectiveness to reduce overall thyroid and nodular volumes in benign compressive goiters assessing changes in Nodule(s) volume(s) and Thyroid lobe volume.

Secondary outcomes

  1. Change in symptoms after TAE.

    Time frame: Follow-ups at 3 months, 6 months and 12 months post-op.

    Assess the impact of TAE on the symptoms related to the goiter as reported by the patient. Using ThyPRO score.

    ThyPRO is designed to evaluate physical, psychological, and social impairments caused by benign thyroid diseases by evaluating :

    • Symptom severity
    • Functional limitations
    • Emotional and social impacts
    • This disease-specific focus supports patient-centered care, clinical decision-making, and outcomes research.
    • Target Population ThyPRO is validated for adults aged 18 and older with benign thyroid diseases.

    The ThyPRO consists of 85 items, grouped into:

    13 multi-item domains: Goiter symptoms (11 items) Hyperthyroid symptoms (8) Hypothyroid symptoms (4) Eye symptoms (8) Tiredness (7) Cognitive impairment (6) Anxiety (6), Depressivity (7) Emotional susceptibility (9) Impaired social life (4), daily life (6), and sex life (2) Cosmetic complaints (6)

    1 global QoL item Each question is rated on a 5-point Likert scale (0 = Not at all to 4 = Completely

  2. Safety level of TAE in compressive goiter: Adverse Events report

    Time frame: Day of embolisation; Follow-ups at 1 week, and 3 months, 6 months and 12 months post-op.

    Evaluate the safety of TAE for the treatment of benign compressive goiter using the Adverse Events report.

  3. Safety level of TAE in compressive goiter: thyroid function tests

    Time frame: At baseline visit, approximately 48 hours after the intervention, and 6 weeks, 3 months, 6 months and 12 months after the intervention. More tests can be done according to the treating physician.

    Monitoring of the effect of the intervention with thyroid function tests.

  4. Safety level of TAE in compressive goiter: parathyroid function tests

    Time frame: At baseline visit, approximately 48 hours after the intervention, and 6 weeks, 3 months, 6 months and 12 months after the intervention. More tests can be done according to the treating physician.

    Describe the effect of the procedure on parathyroid function with PTH and calcium blood levels.

Study contacts

Contact information is provided by the study sponsor or research team.

Laurent Fradet, MD FRCSC

CONTACT

[email protected]

+1-819-346-1110 ext. 14901

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Registry information

Official study title

Thyroid Artery Embolization for the Treatment of Compressive Goiters: a Prospective Cohort Study.

Acronym: TAE

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jan 22, 2026
Registry last updated
Jan 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.